Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV‐2 Omicron in patients with haematological malignancies: A national prospective cohort study
Authors:
- 3 October 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 497-506
Abstract
Summary: Information regarding the protective anti‐SARS‐CoV‐2 antibody levels and the effectiveness of the mRNA vaccines against the Omicron variant in patients with haematological malignancies is limited. We prospectively followed two times BNT162b2 vaccinated oncohaematological patients (n = 1010) without prior COVID‐19 for PCR‐confirmed breakthrough infections during the Alpha/Delta and the Omicron phases of the pandemic. Anti‐S1‐IgG levels were longitudinally monitored in patients who had received the third (booster) vaccine dose. Patients with anti‐S1‐IgG levels p = 0.0001) and severe infections (RR 8.74; 95% CI 3.99–19.1; p < 0.0001). Conversely, the risk of severe COVID‐19 was 500 BAU/mL and neutralizing antibody concentrations >50 U/mL. The risks of breakthrough Omicron infections (HR 0.55; 95% CI 0.32–0.96; p = 0.034) and severe COVID‐19 (HR 0.27; 95% 0.11–0.7; p = 0.0074) were lower among patients who had received the booster dose. In conclusion, low antibody levels are associated with significantly increased risk of both the breakthrough Omicron infections and severe COVID‐19. The third mRNA vaccine dose improved the protection against the Omicron and reduced the risk of severe disease.Keywords
Funding Information
- Abbott Diagnostics
This publication has 34 references indexed in Scilit:
- Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination settingBlood, 2022
- Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccinationBlood, 2022
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipientsBlood, 2021
- Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)Journal of Hematology & Oncology, 2021
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort studyThe Lancet Haematology, 2021
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory TherapiesClinical Microbiology Reviews, 2020
- Overview of Infections in the Immunocompromised HostMicrobiology Spectrum, 2016
- Identification of characteristic IGF2BP expression patterns in distinct B-ALL entitiesBlood Cells, Molecules, and Diseases, 2011